Clinical Efficacy Of Lenalidomide {Revlimid (R)} In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (Cll): Updated Results Of A Phase Ii Clinical Trial.

Introduction: Lenalidomide (L) is an immunomodulatory agent (IMiD®), recently approved for treatment of patients (pts) with previously treated multiple myeloma and del 5q- MDS. Its antitumor effects are reported to be mediated at least in part through modulation of both the cytokine and the immune cellular tumor microenvironment. Clinical efficacy of L in pts with B-CLL has not been investigated previously. In a phase II clinical study, we examined the antileukemic effects of L in pts with relapse (rel) or refractory (ref) B-CLL.